Core Viewpoint - The article highlights the journey of Zhenmai Bio, a Shenzhen-based company that has successfully developed a fully autonomous gene sequencer, overcoming significant challenges in a field dominated by foreign giants. The company has achieved remarkable growth and aims to establish itself as a global leader in the biotechnology sector [1][4]. Company Overview - Zhenmai Bio was founded in 2012 and has become one of only three companies globally capable of providing full-spectrum sequencing instruments. The company has achieved 100% self-research and production of core materials [1][6]. - The company has experienced an average annual revenue growth of 80% to 90%, with projected revenues nearing 400 million yuan this year, reaching a break-even point [1][11]. Technological Development - The company has developed the world's fastest second-generation sequencer, FASTASeq S, which significantly reduces detection times for infections and tumors [1][11]. - The new sequencing chemical technology, CMS, has improved key metrics such as sequencing uniformity and accuracy by tenfold compared to previous industry standards [1][11]. Investment and Support - Early-stage investors played a crucial role in supporting Zhenmai Bio during its initial development phase, allowing the company to focus on technological breakthroughs despite skepticism from the market [1][5]. - A pivotal meeting in 2021 with investor Zheng Weihua led to critical funding that helped the company navigate cash flow challenges and continue its core projects [1][8]. Market Position and Challenges - Zhenmai Bio faces the challenge of establishing its technology as a new industry standard, competing against established players like Illumina, which has defined performance benchmarks for the past two decades [1][11]. - The company is working to build a closed-loop system that integrates equipment, reagents, and ecosystem, which is essential for gaining market acceptance and expanding its reach [1][12]. International Expansion - Zhenmai Bio has begun its internationalization journey, with overseas revenue accounting for 50% of its total. The company has established partnerships in over 60 countries and is pursuing international medical device certifications [1][11]. - The company's vision includes transitioning from "Made in China" to "International Brand," aiming to influence global standards and expand its technological footprint [1][11].

Core Viewpoint - The article highlights the journey of Zhenmai Biotechnology in developing a domestically produced gene sequencer, overcoming significant challenges in a field dominated by foreign companies, and achieving substantial growth and innovation in the industry [1][2]. Company Overview - Zhenmai Biotechnology, founded in 2012, has become one of only three companies globally capable of providing full-flow sequencing instruments, achieving 100% self-research and production of core materials [1][3]. - The company has developed the world's fastest second-generation sequencer, FASTASeq S, which significantly reduces detection times for infections and tumors [6]. Financial Performance - The company reports an average annual revenue growth of 80% to 90%, with projected revenue nearing 400 million yuan this year, reaching a break-even point [1][6]. - Future annual performance growth is expected to maintain between 60% and 80% [1][6]. Technological Challenges - The development of gene sequencers involves complex innovations across over 20 disciplines, including optics, fluid mechanics, and biochemistry, with any shortcomings potentially impacting sequencing accuracy and costs [2][4]. - The industry faces a challenge in defining standards, as the current benchmarks have been set by dominant players like Illumina, which Zhenmai aims to surpass [7]. Market Strategy - Zhenmai's strategy includes a focus on building a closed-loop system that integrates devices, reagents, and ecological systems, which is crucial for gaining market acceptance and establishing a competitive edge [8]. - The company has expanded its international presence, with overseas revenue accounting for 50% and partnerships in over 60 countries [8]. Vision for the Future - The company's vision is to transition from "Made in China" to an internationally recognized brand, aiming to influence global standards and quality in the biotechnology sector [9].